Prevention of post-contrast kidney injury in patients with cancer.

cancer computed tomography post-contrast acute kidney injury

Journal

Drugs in context
ISSN: 1745-1981
Titre abrégé: Drugs Context
Pays: England
ID NLM: 101262187

Informations de publication

Date de publication:
2024
Historique:
received: 08 11 2023
accepted: 24 01 2024
medline: 21 3 2024
pubmed: 21 3 2024
entrez: 21 3 2024
Statut: epublish

Résumé

Post-contrast acute kidney injury is defined as a nephropathy with an increase in serum creatinine of >0.3 mg/dL (or >26.5 μmol/L) or >1.5-times the baseline within 48-72 h of intravascular administration of a contrast medium. Patients with cancer have an increased risk of post-contrast acute kidney injury not only related to the frequent use of contrast medium for computed tomography scans but also to other factors, including the type of tumour, age, oncological therapies, use of other nephrotoxic agents and dehydration. Preventive strategies were developed and may be applied to different risk profiles. Patients at risk may be detected by recently published risk scores.

Identifiants

pubmed: 38510312
doi: 10.7573/dic.2023-11-2
pii: dic-2023-11-2
pmc: PMC10954291
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Informations de copyright

Copyright © 2024 Grassedonio E, Incorvaia L, Guarneri M, Guagnini F, Midiri M.

Déclaration de conflit d'intérêts

Disclosure and potential conflicts of interest: FG is an employee of GE HealthCare, Pharmaceutical Diagnostics (PDx), Milan, Italy. The other authors have no conflicts to declare. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2024/02/dic.2023-11-2-COI.pdf

Auteurs

Emanuele Grassedonio (E)

Biomedicine Department, Neuroscience and Advance Diagnostics, University of Palermo, Palermo, Italy.

Lorena Incorvaia (L)

Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Palermo, Italy.

Marco Guarneri (M)

Nephrology and Dialysis, Azienda Ospedaliera Universitaria "Paolo Giaccone" Polyclinic, Palermo, Italy.

Fabio Guagnini (F)

GE HealthCare Pharmaceutical Diagnostic (PDx), Milan, Italy.

Massimo Midiri (M)

Biomedicine Department, Neuroscience and Advance Diagnostics, University of Palermo, Palermo, Italy.

Classifications MeSH